PET Imaging Is Proud to Offer NETSPOT / Ga-68 PET Scans
PET Imaging Institute of South Florida is proud to offer newly available NETSPOT (Gallium 68-Dotatate) scan:
A novel PET/CT tracer for the detection of Neuro Endocrine Tumors (NETs)
NETSPOT, the new tracer for Gallium 68-Dotatate scan, is the next generation of OCTREOSCAN.
It is a form of octreotide, which binds to a receptor on many NETs called the Somatostatin Receptor. Use of NETSPOT changed patient treatment and management in 71% of patients due to greater specificity compared to Octreoscan.
Gallium PET/CT is more accurate for staging and superior to Octreoscan SPECT in the detection of overall number of lesions in the body as well as organs and bones. Gallium PET/CT also allows for calculation of standardized uptake value, has less whole body radiation, and is performed in less time versus Octreoscan.
NETSPOT™ offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. In a clinical study, NETSPOT™ demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan. Saving just one patient from futile surgery can improve the treatment experience overall and significantly reduce the cost of care by reducing repetitive, often frustrating, and limitless diagnostics.
NETSPOT™ is a significant improvement over existing diagnostic tools and will enable us to more accurately stage and better manage patients.
NETSPOT™ is a novel patented kit developed by AAA for the preparation of gallium Ga 68 dotatate for injection, for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients using Positron Emission Tomography (“PET“).
This product has been designated as an orphan drug by the EMA and the FDA.
Please contact us at 954-981-6668 for further details.
NETSPOT Full U.S. prescribing information
Advanced Accelerator Applications – Product Information